Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
Absci (NASDAQ: ABSI) and Twist Bioscience announced a collaboration to design a novel therapeutic using generative AI. The partnership combines Absci's AI drug creation platform with Twist's DNA synthesis technology to accelerate pharmaceutical R&D. The companies will develop a therapeutic candidate against an undisclosed target, utilizing Absci's AI de novo design capabilities and Twist's silicon-based synthesis platform, including Multiplexed Gene Fragments for testing antibody candidates. Both companies plan to seek a partner for clinical development and commercialization. This program adds to Absci's portfolio of collaborations with companies like AstraZeneca and Merck.
Absci (NASDAQ: ABSI) e Twist Bioscience hanno annunciato una collaborazione per progettare una nuova terapia utilizzando l'IA generativa. Il partenariato combina la piattaforma di creazione di farmaci AI di Absci con la tecnologia di sintesi del DNA di Twist per accelerare la ricerca e sviluppo nel settore farmaceutico. Le aziende svilupperanno un candidato terapeutico contro un target non rivelato, utilizzando le capacità di design de novo basate sull'IA di Absci e la piattaforma di sintesi basata su silicio di Twist, inclusi i frammenti genici multiplex per testare i candidati anticorpali. Entrambe le aziende prevedono di cercare un partner per lo sviluppo clinico e la commercializzazione. Questo programma si aggiunge al portafoglio di collaborazioni di Absci con aziende come AstraZeneca e Merck.
Absci (NASDAQ: ABSI) y Twist Bioscience anunciaron una colaboración para diseñar una nueva terapia utilizando IA generativa. La asociación combina la plataforma de creación de fármacos con IA de Absci con la tecnología de síntesis de ADN de Twist para acelerar la I+D farmacéutica. Las empresas desarrollarán un candidato terapéutico contra un objetivo no revelado, utilizando las capacidades de diseño de novo de Absci y la plataforma de síntesis basada en silicio de Twist, incluyendo fragmentos de genes multiplexados para probar candidatos a anticuerpos. Ambas empresas planean buscar un socio para el desarrollo clínico y la comercialización. Este programa se suma al portafolio de colaboraciones de Absci con compañías como AstraZeneca y Merck.
Absci (NASDAQ: ABSI)와 Twist Bioscience는 생성적 AI를 사용하여 새로운 치료제를 설계하기 위한 협업을 발표했습니다. 이 파트너십은 Absci의 AI 약물 생성 플랫폼과 Twist의 DNA 합성 기술을 결합하여 제약 R&D를 가속화합니다. 두 회사는 비공개 표적에 대한 치료 후보 물질을 개발하며, Absci의 AI 기반 신약 설계 기능과 Twist의 실리콘 기반 합성 플랫폼을 활용하고, 항체 후보를 테스트하기 위해 다중 유전자 조각을 포함합니다. 두 회사는 임상 개발 및 상용화를 위한 파트너를 찾을 계획입니다. 이 프로그램은 AstraZeneca와 Merck와 같은 회사들과의 Absci 협업 포트폴리오에 추가됩니다.
Absci (NASDAQ: ABSI) et Twist Bioscience ont annoncé une collaboration pour concevoir une nouvelle thérapie en utilisant l'IA générative. Ce partenariat combine la plateforme de création de médicaments par IA d'Absci avec la technologie de synthèse de l'ADN de Twist pour accélérer la recherche et le développement pharmaceutiques. Les entreprises développeront un candidat thérapeutique contre une cible non divulguée, en utilisant les capacités de conception de novo d'Absci et la plateforme de synthèse basée sur le silicium de Twist, y compris des fragments de gènes multiplexés pour tester des candidats anticorps. Les deux entreprises prévoient de rechercher un partenaire pour le développement clinique et la commercialisation. Ce programme s'ajoute au portefeuille de collaborations d'Absci avec des entreprises telles qu'AstraZeneca et Merck.
Absci (NASDAQ: ABSI) und Twist Bioscience haben eine Zusammenarbeit zur Entwicklung einer neuartigen Therapie unter Einsatz von generativer KI bekannt gegeben. Die Partnerschaft kombiniert die KI-gestützte Arzneimittelentwicklung von Absci mit der DNA-Synthesetechnologie von Twist, um die pharmazeutische Forschung und Entwicklung zu beschleunigen. Die Unternehmen werden einen therapeutischen Kandidaten gegen ein nicht offengelegtes Ziel entwickeln, indem sie die de novo Designfähigkeiten von Absci und die siliziumbasierte Synthesetechnologie von Twist nutzen, einschließlich mehrfacher Genfragmente zur Testung von Antikandidaten. Beide Unternehmen planen, einen Partner für die klinische Entwicklung und Vermarktung zu suchen. Dieses Programm ergänzt das Portfolio von Absci mit Kooperationen mit Unternehmen wie AstraZeneca und Merck.
- Strategic collaboration with established biotech company Twist Bioscience
- Expansion of partnership portfolio alongside major pharmaceutical companies
- Potential for accelerated drug development through combined AI and DNA synthesis technologies
- Partnership requires additional third party for clinical development and commercialization
- Target and therapeutic candidate details remain undisclosed
- No immediate revenue impact disclosed
Insights
This collaboration marks a strategic advancement in AI-driven drug development, combining Absci's generative AI capabilities with Twist's DNA synthesis technology. The partnership demonstrates significant potential for accelerating therapeutic antibody development through innovative technological synergy.
The deal structure, focusing on joint development followed by partnering for clinical development, represents a capital-efficient approach to drug development. For Absci, this adds another notable collaboration alongside existing partnerships with major pharmaceutical companies like AstraZeneca and Merck, validating their AI platform's credibility.
While financial terms aren't disclosed, this collaboration could strengthen both companies' market positions in the competitive biotech space. The focus on an undisclosed target with potential impact across multiple disease areas suggests broad commercial potential.
The collaboration showcases a sophisticated integration of two cutting-edge platforms: Absci's generative AI for antibody design and Twist's silicon-based DNA synthesis technology. This represents an important step in validating AI's practical application in drug discovery, particularly in the complex field of antibody development.
The partnership's technical approach, combining de novo design capabilities with multiplexed gene fragment testing, creates a robust validation framework for AI-generated candidates. This integrated workflow could significantly reduce the time and cost typically associated with traditional antibody discovery methods, potentially creating a competitive advantage in the biologics space.
Collaboration brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibody
VANCOUVER, Wash. and SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI) a data-first generative AI drug creation company, and Twist Bioscience Corporation (NASDAQ: TWST) a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today unveiled a collaboration to design a novel therapeutic using generative AI.
“Bringing together two leaders in biotechnology innovation represents an opportunity to accelerate pharmaceutical R&D,” said Absci Founder & CEO Sean McClain. “We are excited to strengthen our relationship with Twist and leverage the power of our shared platforms to bring better biologics to patients faster.”
Through this new collaboration, Absci and Twist will design a novel therapeutic candidate against an undisclosed target using Absci’s advanced generative AI platform and Twist’s synthetic DNA platform. The program will leverage Absci’s AI de novo design capabilities and Twist’s silicon-based synthesis platform, including its Multiplexed Gene Fragments for the testing and validation of antibody candidates designed using Absci’s generative AI technology platform. Twist and Absci intend to seek a partner for human clinical development and commercialization.
“We have been working with Absci for several years and look forward to extending our collaboration beyond a preferred supplier to leverage their AI platform along with Twist’s capabilities to discover antibodies to a key biological target that potentially impacts multiple disease areas,” said Emily M. Leproust, Ph.D., CEO and cofounder of Twist Bioscience.
This program adds to Absci’s growing portfolio of collaboration programs with industry-leading pharmaceutical companies such as AstraZeneca and Merck, as well as with leading academic institutes such as Memorial Sloan Kettering Cancer Center. In addition to its partnered programs, Absci continues to advance an internal pipeline of multiple drug candidates.
For this program, Twist will apply products from its SynBio portfolio developed for antibody discovery including Multiplexed Gene Fragments, Express portfolio and synthesis of long DNA. This partnership illustrates the value of Twist’s platform from individual pieces of DNA all the way through antibody discovery.
About Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research. Follow us on LinkedIn | X | YouTube | Instagram
Absci Forward-Looking Statements
Certain statements in this press release that are not historical facts are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “may,” “pursues,” “anticipates,” “plans,” “believes,” “aims,” “potential,” “forecast,” “estimates,” “extends,” “expects,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding the capabilities of our Integrated Drug Creation platform, our technology development efforts and the application of those efforts, the potential benefits of our partnership with Twist, the plans and success of our current and future partnerships and the ability to generate advancements towards treating disease using generative AI drug creation to accelerate the development of novel candidate therapies, the anticipated value to us under our partnerships, and our internal therapeutic asset programs, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to our ability to effectively collaborate on research, drug discovery and development activities with our partners or potential partners, our dependence on third parties to support our internal development programs, including for the manufacture and supply of preclinical and clinical supplies of our product candidates or components thereof, our existing and potential partners’ ability and willingness to pursue the development and commercialization of programs or product candidates under the terms of our partnership agreements, and overall market conditions and regulatory developments that may affect our and our partners’ activities under these agreements, along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Twist Bioscience Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential benefits of our partnership with Absci and the success of our partnership and the ability to generate advancements towards treating disease using generative AI drug creation to accelerate the development of novel candidate therapies. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period will depend heavily on the success of our existing products and the development and commercialization of additional products in the synthetic biology, biologic drug and data storage industries; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the SEC on November 21, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Absci Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Absci Media Contact
press@absci.com
Twist Investor Contact:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com
Twist Media Contact:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com
FAQ
What is the purpose of Absci's collaboration with Twist Bioscience announced on October 31, 2024?
What technologies will ABSI use in the Twist Bioscience collaboration?
Who are Absci's (ABSI) other major collaboration partners?
